| 货号 | 13101-50ug |
| 描述 | A common metabolic pathway for several prostaglandins (PG), including PGE2, involves the reduction of the double bond between C-13 and C-14 and oxidation of the hydroxyl group at C-15, producing 13,14-dihydro-15-keto PGs. The removal of four carbons at the α-terminus and oxidation of the terminal ω-carbon produces the abundant urinary metabolites, including tetranor PGEM.1 13,14-dihydro-15-keto tetranor PGE2 is a potential metabolite of PGE2. It would be produced from the known metabolite 13,14-dihydro-15-keto PGE2 (Item No. 14650), which is known to have a short plasma half-life.2,3,4 |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Hamberg, M. Inhibition of prostaglandin synthesis in man. Biochemical and Biophysical Research Communications 49, 720-726 (1972). 2.Bothwell, W.,Verburg, M.,Wynalda, M., et al. A radioimmunoassay for the unstable pulmonary metabolites of prostaglandin E1 and E2: An indirect index of their in vivo disposition and pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics 220, 229-235 (1982). 3.Fitzpatrick, F.A.,Aguirre, R.,Pike, J.E., et al. The stability of 13,14-dihydro-15 keto-PGE2. Prostaglandins 19, 917-931 (1980). 4.Granström, E.,Hamberg, M.,Hansson, G., et al. Chemical instability of 15-keto-13,14-dihydro-PGE2: The reason for low assay reliability. Prostaglandins 19, 933-945 (1980). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥95% |
| 计算分子量 | 298.4 |
| 分子式 | C16H26O5 |
| CAS号 | 20675-85-8 |
| 稳定性 | ≥ 6 months |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |